IDEC-Y2B8

{
  "id": "MLC-T-ONC-004123",
  "term": "IDEC-Y2B8",
  "field": "Oncology and biomedicine",
  "definition": "A drug used with the drug rituximab to treat certain types of B-cell non-Hodgkin lymphoma. It is also being studied in the treatment of other types of B-cell tumors. IDEC-Y2B8 contains a monoclonal antibody that binds to a protein called CD20, which is found on B cells. It also contains a radioactive substance called yttrium Y 90, which may help kill cancer cells. IDEC-Y2B8 is a type of radioimmunoconjugate. Also called 90Y-ibritumomab tiuxetan, 90Y-Zevalin, and yttrium Y 90-ibritumomab tiuxetan.",
  "expansions": [
    "90Y-ibritumomab tiuxetan",
    "90Y-Zevalin",
    "yttrium Y 90-ibritumomab tiuxetan"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/idec-y2b8/"
}